Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a note issued to investors on Thursday. The firm set a “hold” rating on the stock.

Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $3.30 target price on shares of Aspira Women’s Health in a research report on Wednesday, April 10th.

Aspira Women’s Health Price Performance

AWH stock opened at $1.64 on Thursday. The company has a 50 day moving average price of $2.75 and a 200 day moving average price of $3.53. Aspira Women’s Health has a fifty-two week low of $1.53 and a fifty-two week high of $6.75. The stock has a market capitalization of $20.42 million, a PE ratio of -1.13 and a beta of 1.50.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings data on Tuesday, May 21st. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 163.95%. The company had revenue of $2.15 million during the quarter, compared to the consensus estimate of $2.10 million. During the same quarter last year, the firm earned ($10.94) EPS. As a group, equities analysts expect that Aspira Women’s Health will post -1.3 earnings per share for the current fiscal year.

Institutional Trading of Aspira Women’s Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Northeast Financial Consultants Inc acquired a new position in shares of Aspira Women’s Health in the 3rd quarter valued at $126,000. Quantum Private Wealth LLC grew its holdings in shares of Aspira Women’s Health by 76.8% in the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock valued at $205,000 after buying an additional 21,788 shares during the period. Finally, B. Riley Wealth Advisors Inc. grew its holdings in shares of Aspira Women’s Health by 39.0% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock valued at $672,000 after buying an additional 35,177 shares during the period. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.